Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Articles Tagged With: intravenous

  • Subcutaneous IVIG for Treatment of Myasthenia Gravis

    A Phase II trial comparing subcutaneous (SC) administration of pooled immunoglobulin to intravenous (IV) administration of immunoglobulin in 23 patients with seropositive myasthenia gravis demonstrated a stable course after transition from IV to SC.

  • Mechanical Thrombectomy with or Without Intravenous Thrombolysis?

    Current stroke treatment guidelines recommend combined use of intravenous thrombolysis with alteplase prior to endovascular thrombectomy for patients with large vessel occlusion. However, there continues to be controversy surrounding this recommendation, and these investigators undertook a systematic review and meta-analysis of completed therapeutic trials to help resolve the controversy.

  • Mechanical Thrombectomy with or Without Intravenous Thrombolysis?

    Current stroke treatment guidelines recommend combined use of intravenous thrombolysis with alteplase prior to endovascular thrombectomy for patients with large vessel occlusion. However, there continues to be controversy surrounding this recommendation, and these investigators undertook a systematic review and meta-analysis of completed therapeutic trials to help resolve the controversy.

  • What Is the Right Dose of Immunoglobulin to Treat CIDP?

    In this comparative trial of different doses of intravenous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy, higher doses appeared to result in a higher percentage of patients who improved. However, there was no control group and there were many confounding issues that make it difficult to reach a definitive conclusion around optimal dosing.

  • Oral vs. IV Iron for the Treatment of Iron-Deficiency Anemia in Pregnant Women

    Compared to oral iron, intravenous iron reduced maternal anemia at delivery (40% vs. 85%, P = 0.039), and rates of maternal hemoglobin < 10 g/dL were lower with intravenous iron compared to oral iron (10% vs. 54%, P = 0.029). Rates of mild to moderate adverse events were similar between the two groups, and no severe adverse reactions were noted with intravenous iron.

  • Intravenous Iron: Does This Therapy Increase the Risk of Infection?

    In this systematic review and meta-analysis, among all populations, intravenous iron was associated with a slight increased risk of infection (relative risk, 1.17; 95% confidence interval, 1.04-1.31) compared to oral iron or no iron. However, there was no difference in mortality or length of hospital stay.

  • Mortality and Costs of Status Epilepticus

    In an analysis of a large group of patients hospitalized with status epilepticus, based on an administrative database, patients who required a third line of intravenous anesthetic agents had the highest mortality and highest hospital costs.

  • Genetic Biomarkers of Immunoglobulin Response in Patients with CIDP

    Nearly 25% of patients with chronic inflammatory demyelinating polyneuropathy (CIDP) have a poor response to intravenous immunoglobulin treatment. Variations in the PRF1 and FCGR2B genes in CIDP patients offer insights into the heterogenous treatment response.

  • Should Patients with Ischemic Stroke and Large Vessel Occlusions Go Directly to Endovascular Thrombectomy?

    Endovascular mechanical thrombectomy has become the standard treatment for patients with acute ischemic stroke caused by large vessel occlusion in both the anterior and posterior circulations. This is predicated on the ability to perform the procedure in a timely fashion or based on a mismatch between the size of infarction and brain perfusion.

  • Treatment of Central Retinal Artery Occlusion with Intravenous Thrombolysis

    Central retinal artery occlusion is a serious threat to vision caused by interruption of the blood supply to the retina and leading to sudden, painless loss of vision in one eye. For 30 years there have been anecdotal reports and small case series suggesting that intravenous thrombolysis might be beneficial in this disorder, but none of the stroke treatment guidelines have incorporated thrombolysis as definitive treatment for this disorder.